Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

I-015

Supelco

Itraconazole solution

2.0 mg/mL (Methanol with 1% 1M HCl), ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C35H38Cl2N8O4
Número de CAS:
84625-61-6
Peso molecular:
705.63
Código UNSPSC:
41116107
NACRES:
NA.24

grado

certified reference material

Formulario

liquid

Características

(Snap-N-Spike®)

envase

ampule of 1 mL

fabricante / nombre comercial

Cerilliant®

concentración

2.0 mg/mL (Methanol with 1% 1M HCl)

técnicas

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicaciones

clinical testing

Formato

single component solution

temp. de almacenamiento

−20°C

cadena SMILES

Clc1c(ccc(c1)Cl)[C@@]3(O[C@H](CO3)COc4ccc(cc4)N5CCN(CC5)c6ccc(cc6)[n]7[c]([n](nc7)C(CC)C)=O)C[n]2ncnc2

InChI

1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1

Clave InChI

VHVPQPYKVGDNFY-ZPGVKDDISA-N

Descripción general

Itraconazole is an antifungal drug prescribed for oral or intravenous treatment of fungal infections. The drug is sold under trade names such as Sporanoxor Onmel®. This Certified Spiking Solution® is suitable as starting material for calibrators, controls, or linearity standards for clinical and diagnostic testing or therapeutic drug monitoring of itraconazole in patient blood, serum, or plasma samples by LC-MS/MS or HPLC.

Información legal

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Onmel is a registered trademark of Merz Pharmaceuticals, LLC
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Met. Corr. 1 - STOT SE 1

Órganos de actuación

Eyes,Central nervous system

Código de clase de almacenamiento

3 - Flammable liquids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

49.5 °F - closed cup

Punto de inflamabilidad (°C)

9.7 °C - closed cup

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Ming Yao et al.
Biomedical chromatography : BMC, 23(7), 677-691 (2009-03-25)
Itraconazole represents an important therapeutic option for the treatment of fungal infections. Itraconazole undergoes rapid metabolism to form hydroxyitraconazole, which also contributes to the anti-fungal activity exhibited by the parent compound. Since both itraconazole and hydroxyitraconazole are effective inhibitors of
Johan Maertens et al.
The Journal of antimicrobial chemotherapy, 56 Suppl 1, i33-i38 (2005-08-27)
The incidence of systemic fungal infections has risen sharply in the last two decades, reflecting a rise in the number of patients who are predisposed to these diseases because they are immunosuppressed or immunocompromised. The growing use of intensive chemotherapy
Jodi Lestner et al.
Expert opinion on drug metabolism & toxicology, 9(7), 911-926 (2013-05-07)
Fungal infections are a major source of global morbidity and mortality. Itraconazole is a triazole antifungal agent that is widely used for the prevention and treatment of fungal infection. While newer antifungal agents are now available, itraconazole is an orally
Takashi Ishiguro et al.
Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 47(4), 296-303 (2009-05-22)
We report the case of a 75-year-old woman with mucoid impaction of the bronchi (MIB) due to Schizophyllum commune who improved with itraconazole (ITCZ) administration and relapsed after discontinuation of the drug. She improved again after readministration of ITCZ, and
[Pharmacological, pharmacokinetic, and clinical profile of itraconazole oral solution (ITRIZOLE Oral Solution 1%)].
Hisaya Otani et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 130(1), 69-76 (2007-07-20)
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico